Cardiovascular disease (CVD) is responsible for one in four premature deaths in the UK, making the disease one of the biggest causes of mortality across the country. It is also one of the largest causes of life expectancy gaps, with people in the most deprived 10% of the population being almost twice as likely to died as a result of CVD.
In southeast London, the effects of CVD are exacerbated by very high levels of deprivation. To improve diagnosis and intervention for underserved communities in the region, South East London Integrated Care Board (ICB), King's Health Partners Population Health and Equity programme and Novartis developed three community-based pilot projects:
The Health Innovation Network South London lead with the evaluation of the project, exploring whether the initiatives increased engagement with hardly reached communities to support improvements related to CVD prevention, care and patient identification.
The mixed-method study examined the approaches taken as well as the perceived impact of the three projects. Interviews with staff, stakeholders and patients also described the support provided by the pharmaceutical company and the views of staff and patients of the company's involvement in the CVD projects.
Conclusion
All three projects were successful in engaging with their target communities, with most patients who attended a service continuing for the duration of its delivery. Patients also felt empowered to undertake behavioural change to support better CVD related outcomes.
The following areas are suggested for improving community engagement with these services:
The projects also demonstrated the potential to enhance health outcomes and innovative patient care approaches through collaborations between the NHS and pharmaceutical companies.